Continuous-flow ventilation with VENTIJET in moderate ARDS: a pilot safety and feasibility study

Area of Science:

• Critical Care Medicine
• Respiratory Physiology
• Mechanical Ventilation

Background:

• Acute respiratory distress syndrome (ARDS) is linked to high mortality and ventilator-induced lung injury.
• Continuous-flow ventilation (CFV) offers potential benefits but has faced technical challenges.
• The VENTIJET is a new nozzle-based CFV ventilator for critically ill adults.

Purpose of the Study:

• To evaluate the feasibility and safety of the VENTIJET CFV system in adult patients with moderate ARDS.
• To assess preliminary effects on gas exchange and respiratory mechanics.

Main Methods:

• A prospective, single-center pilot study involving intubated adults with moderate ARDS.
• Patients initially received conventional ventilation, then VENTIJET CFV for up to 24 hours.
• Primary endpoints focused on feasibility and safety; secondary endpoints included gas exchange and respiratory mechanics.

Main Results:

• VENTIJET ventilation was successfully administered to all 14 enrolled patients without adverse events.
• Oxygenation (PaO₂/FiO₂) showed a non-significant trend towards improvement (200 vs. 192 mm Hg).
• Modest improvements in respiratory system compliance were observed over 24 hours, with stable CO₂ elimination and hemodynamics.

Conclusions:

• The VENTIJET CFV system is feasible and safe for patients with moderate ARDS.
• It effectively maintains gas exchange while offering potential benefits in respiratory mechanics.
• Further investigation in larger, controlled trials across the ARDS spectrum is recommended.